Novel biologics for the treatment of pediatric severe asthma

Amelia Licari, Riccardo Castagnoli, Enrico Tondina, Giorgia Testa, Giuseppe Fabio Parisi, Alessia Marseglia, Ilaria Brambilla, Gian Luigi Marseglia

Research output: Contribution to journalReview articlepeer-review

Abstract

Estimated to represent less than 5% of all asthmatic patients, children with severe asthma experience troublesome persistent symptoms, life-threatening attacks and side effects by oral corticosteroid treatment, that significantly impact on the quality of life and on economic costs. An accurate understanding of the mechanisms of the disease has been crucial for the discovery and development of biological therapies, for which children with severe asthma are candidates. The aim of this review is to discuss the use of approved biologics for severe asthma, providing updated evidence of novel targeted therapies in the pediatric age range.

Original languageEnglish
Pages (from-to)195-204
Number of pages10
JournalCurrent Respiratory Medicine Reviews
Volume15
Issue number3
DOIs
Publication statusPublished - 2019

Keywords

  • Benralizumab
  • Children
  • Dupilumab
  • Mepolizumab
  • Omalizumab
  • Reslizumab
  • Severe asthma

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Novel biologics for the treatment of pediatric severe asthma'. Together they form a unique fingerprint.

Cite this